One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy.

Abstract

To evaluate the functional and structural outcomes of intravitreal conbercept monotherapy using a "3 + pro re nata (PRN)" regimen in treatment-naïve subjects with polypoidal choroidal vasculopathy (PCV) up to 12months. Thirty subjects (30 eyes) with PCV participated in this interventional, retrospective study. All subjects received intravitreal injections of 0.5mg (0.05ml) conbercept using a "3 + PRN" regimen for 12months. The changes in best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, polyp lesion area, and regression rate were evaluated at baseline, month 3, and month 12. At the study end-point, BCVA improved significantly from 52.80 ± 17.17 ETDRS letters at baseline to 62.20 ± 18.96 letters (P< 0.001), with a mean gain of 9.40 ± 14.97 letters. The central retinal thickness (CRT) significantly reduced from 454.93 ± 147.31μm at baseline to 308.73 ± 106.80μm (P< 0.001) at end-point, and the total macular volume (TMV) decreased from 9.51 ± 1.04mm3 at baseline to 8.32 ± 0.84mm3 at end-point (P< 0.001). The mean volume of pigment epithelial detachment (PED) decreased from 0.73 ± 0.97mm3 at baseline to 0.48 ± 0.71mm3 (P<0.05) at month 3. At month 12, the mean volume of PED was 0.57 ± 0.80mm3 (P> 0.05 compared to baseline). After the 3-monthly loading injections, 6 eyes (20.0%) showed complete polyp regression, whereas a total of 19 eyes (63.5%) showed complete regression at month 12. The average injections given per subject were 7.70 ± 1.81. Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.